Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90011 + Standard of Care in First-Line ES-SCLC
NCT03850067Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pulrodemstat in small cell lung cancer (SCLC) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Mar 2019; status: completed.
02
Drugs
pulrodemstat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03850067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850067.